Drug Trial Radar · NCT06550895
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
11
Actual
Start
Sep 16, 2024
Primary completion
Aug 26, 2027
Study completion Aug 26, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Aug 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).
Conditions
- Multiple Myeloma
Interventions
Cilta-celDrug
Cilta-cel infusion will be administered intravenously.
TalquetamabDrug
Talquetamab will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AE) by Severity According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0Time frame: Up to 3 years and 5 months
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
University of Iowa Hospital and Clinics
Iowa City, Iowa
Norton Cancer Institute
Louisville, Kentucky
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Icahn School of Medicine at Mount Sinai
New York, New York
University of Pennsylvania
Philadelphia, Pennsylvania
Royal Prince Alfred Hospital
Camperdown, Australia
Austin Hospital
Heidelberg, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
The Alfred Hospital
Melbourne, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.